EpiCast Report: Diabetic Foot Ulcers-Epidemiology Forecast to 2025
January 2017
59
About the Report
About the Report
EpiCast Report: Diabetic Foot Ulcers-Epidemiology Forecast to 2025
Summary
Diabetic foot ulcers (DFUs) are a common and disabling condition among people with diabetes. Globally, the prevalence of DFU among people with diabetes varies widely, ranging from 5.1% in the UK to approximately 11.9% in Algeria. The lifetime risk of developing a DFU in an individual with diabetes is approximately 25%. DFUs have become an increasingly significant public health concern in both the developed and the developing world, and are a major cause of hospitalizations and the leading cause of lower-extremity amputations in diabetics. Given the increasing prevalence of diabetes coupled with the aging population, the burden of complications related to diabetes such as DFUs is likely to increase over the next 20 years.
GlobalData epidemiologists forecast that the diagnosed incident cases of DFU among the diagnosed diabetic population in the 7 MM will increase from 1,060,036 cases in 2015 to 1,487,754 cases in 2025, at an Annual Growth Rate (AGR) of 4.03%. In the 7MM, GlobalData epidemiologists forecast that the total prevalent cases of DFUs among the diagnosed diabetic population will increase from 4,975,656 cases in 2015 to 7,063,884 cases in 2025, at an AGR of 4.20%.
GlobalData epidemiologists forecast the diagnosed incident cases and total prevalent cases of DFU in the 7MM from 2015-2025 using studies published in peer-reviewed journals that provided age- and sex-specific diagnosed incidence and total prevalence of DFU in the respective markets. GlobalData epidemiologists further segmented the diagnosed incident cases of DFU by classification of DFUs (neuropathic, ischemic, and neuroischemic). Additionally, the report includes a forecast of the cases of diabetic foot infection and peripheral artery disease (PAD) among the diagnosed incident population of DFUs in the 7MM. GlobalData epidemiologists ensured that the forecast methodology was consistent across all the 7MM to allow for a meaningful comparison of the forecast numbers across these markets.
Scope
The Diabetic Foot Ulcers (DFU) EpiCast Report provides an overview of the risk factors and global trends of DFU in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases of DFU and total prevalent cases of DFU (diagnosed and undiagnosed cases), which are segmented by sex and age. The diagnosed incident cases of DFU are further segmented by classification of DFUs (neuropathic, ischemic, and neuroischemic). Additionally, the report includes a forecast of the cases of diabetic foot infection and peripheral artery disease (PAD) among the diagnosed incident population of DFUs in the 7MM.
The DFU epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to Buy
The DFU EpiCast report will allow you to
Develop business strategies by understanding the trends shaping and driving the global DFU market.
Quantify patient populations in the global DFU market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for DFU therapeutics in each of the markets covered.
Identify the percentage of DFU diagnosed incident cases and total prevalent cases by various clinical segmentations.
Products
Table of Contents
Table of Contents
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 7
2 Epidemiology 8
2.1 Disease Background 8
2.2 Risk Factors and Comorbidities 9
2.3 Global Trends 11
2.3.1 Diagnosed Incidence and Total Prevalence 12
2.4 Forecast Methodology 15
2.4.1 Sources Used Tables 16
2.4.2 Forecast Assumptions and Methods 18
2.4.3 Sources Not Used 30
2.5 Epidemiological Forecast of DFU (2015-2025) 31
2.5.1 Diagnosed Incident Cases of DFU Among the Diagnosed Diabetic Population 31
2.5.2 Total Prevalent Cases of DFU Among the Diagnosed Diabetic Population 40
2.6 Discussion 47
2.6.1 Epidemiological Forecast Insight 47
2.6.2 Limitations of the Analysis 48
2.6.3 Strengths of the Analysis 49
3 Appendix 50
3.1 Bibliography 50
3.2 About the Authors 55
3.2.1 Epidemiologists 55
3.2.2 Reviewers 55
3.2.3 Global Director of Therapy Analysis and Epidemiology 56
3.3 About GlobalData 57
3.4 About EpiCast 57
3.5 Disclaimer 58
List of Figure
1.2 List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of DFU, Ages ?20 Years, Both Sexes, N, Selected Years 2015-2025 32
Figure 2: 7MM, Diagnosed Incident Cases of DFU, by Age, Both Sexes, N, 2015 34
Figure 3: 7MM, Diagnosed Incident Cases of DFU, Ages ?20 Years, by Sex, N , 2015 36
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of DFU, Ages ?20 Years, by Sex, Cases per 100,000 Diabetic Population, 2015 37
Figure 5: 7MM, Diagnosed Incident Cases of DFU by Classification, Both Sexes, Ages ?20 Years, 2015 38
Figure 6: 7MM, Diabetic Foot Infection Cases Among the DFU-Diagnosed Incident Population, Both Sexes, Ages ?20 Years, 2015 39
Figure 7: 7MM, PAD Cases Among the DFU-Diagnosed Incident Population, Both Sexes, Ages ?20 Years, 2015 40
Figure 8: 7MM, Total Prevalent Cases of DFU, Ages ?20 Years, Both Sexes, N, Selected Years 2015-2025 42
Figure 9: 7MM, Total Prevalent Cases of DFU, by Age, Both Sexes, N, 2015 44
Figure 10: 7MM, Total Prevalent Cases of DFU, Ages ?20 Years, by Sex, N , 2015 46
Figure 11: 7MM, Age-Standardized Total Prevalence of DFU, Ages ?20 Years, by Sex, %, 2015 47
List of Table
1.1 List of Tables
Table 1: Risk Factors and Comorbidities of DFUs 10
Table 2: 7MM, Diagnosed Incidence of DFU Among the Diabetic Population from 1993-2008 12
Table 3: 7MM, Total Prevalence of DFU Among the Diabetic Population from 1990-2008 12
Table 4: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of DFU Among the Diagnosed Diabetic Population 16
Table 5: 7MM, Sources Used for the Classification of DFUs Among the DFU-Diagnosed Incident Population 17
Table 6: 7MM, Sources Used to Forecast Diabetic Foot Infection and PAD Cases Among the DFU-Diagnosed Incident Population 17
Table 7: 7MM, Sources Used to Forecast the Total Prevalent Cases of DFU Among the Diagnosed Diabetic Population 18
Table 8: 7MM, Sources Not Used in Epidemiological Analysis of DFU 30
Table 9: 7MM, Diagnosed Incident Cases of DFU, Ages ?20 Years, Both Sexes, N, Selected Years 2015-2025 32
Table 10. 7MM, Diagnosed Incident Cases of DFU, by Age, Both Sexes, N (Row %), 2015 33
Table 11: 7MM, Diagnosed Incident Cases of DFU, by Sex, Ages ?20 Years, N (Row %), 2015 35
Table 12: 7MM, Total Prevalent Cases of DFU, Ages ?20 Years, Both Sexes, N, Selected Years 2015-2025 41
Table 13. 7MM, Total Prevalent Cases of DFU, by Age, Both Sexes, N (Row %), 2015 43
Table 14: 7MM, Total Prevalent Cases of DFU, by Sex, Ages ?20 Years, N (Row %), 2015 45
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.